Rani Therapeutics vs Vistagen Therapeutics
Rani Therapeutics reported revenue of $2 million in fiscal 2025, 1.2 times Vistagen Therapeutics' $1 million in fiscal 2026. Rani Therapeutics' revenue grew 58.9% in its latest year, and Vistagen Therapeutics' grew 161.1%. Rani Therapeutics had an operating margin of -2346.0%, against -5683.7% at Vistagen Therapeutics. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.
Side by side
| Rani Therapeutics | Vistagen Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Mar 31, 2026 |
| Revenue | $2M | $1M |
| Revenue growth | 58.9% | 161.1% |
| Revenue growth a year, last 5 years | 26.2% | 3.4% |
| Gross margin | — | — |
| Operating margin | −2,346.0% | −5,683.7% |
| Net margin | −1,817.1% | −5,491.3% |
| Free cash flow | −$19M | — |
| Free cash flow margin | −1,151.4% | — |
| Return on capital | −127.1% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 132.3% | 23.3% |
| Last close | $0.58 | $0.19 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $50,040, sold $301 | — |
| Piotroski F-score | 4 of 8 | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Rani TherapeuticsVistagen Therapeutics
Operating margin
Percent of revenue
Rani TherapeuticsVistagen Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Rani TherapeuticsVistagen Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Rani Therapeutics and Vistagen Therapeutics pages.